Lilly Invests $1.5 Billion in New Manufacturing Facilities

We bring our purpose to life by discovering and developing innovative medicines. Over the last nine years, we’ve delivered 19 new medicines and hope to introduce several more by the end of the year. To ensure a reliable supply of these new medicines, we’re expanding our manufacturing footprint with investments in new facilities in North Carolina, Indiana and Ireland.

Lilly executives and local officials broke ground on March 27, 2023, for our new state-of-the-art biotech manufacturing campus in Raheen, Co. Limerick, Ireland. This nearly $1 billion investment at our next-generation biotech facility will be Lilly’s most technically advanced manufacturing site for existing monoclonal antibodies. This site will produce existing products and our pipeline of clinical products by 2026. The campus is expected to employ around 300 people across various disciplines. Recruitment will begin in early 2023.

"Lilly is entering an exciting period of growth, and we are committed to delivering innovative medicines to patients around the world,” said Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations. "Expanding our manufacturing footprint in North Carolina and Ireland enables us to continue to produce today’s medicines while providing additional capacity to manufacture the medicines of tomorrow.”

In Concord, Lilly plans to invest $1 billion to create a new injectable products and devices manufacturing site, along with nearly 600 jobs. Additionally, the company plans to invest $500 million in Limerick to create a new biologics active ingredients site, as well as more than 300 jobs. Lilly will hire scientists, engineers and manufacturing personnel at each site to ensure we can reach more people with life-changing medicines at a greater pace.

In 2020, Lilly made our first manufacturing investment in North Carolina at Raleigh/Durham’s Research Triangle Park, the largest research park in the U.S. Together with our initial investment, the new facility in Concord will allow Lilly to take full advantage of the state’s reliable manufacturing workforce and partner with top-tier research and medical institutions as well as community colleges with strong programs in science, technology, engineering and math (STEM).

While Lilly’s presence in North Carolina is newly established, the company has been in Ireland for more than 40 years. Lilly’s first investment in Ireland began in 1978, with the purchase of a farm in the West Cork countryside of Dunderrow, near Kinsale. Since our initial investment, Lilly has continued to grow our footprint in Ireland in part because of supportive government policies that value life science discoveries and innovation. With this new investment in Limerick, Lilly will expand our manufacturing network for biologic active ingredients, support demand for existing products and play a key role in bringing our robust pipeline, including our promising neurodegeneration portfolio, to people around the world.

Lilly expects to make more investments in manufacturing as we work to create medicines, in areas like diabetes, neurodegeneration, cancer and immunology, that make life better for people around the world.